Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
9
|
pubmed:dateCreated |
1996-2-20
|
pubmed:abstractText |
For two large California dairy herds with twice daily milking, 171 infected quarters of lactating cows with mild clinical mastitis were randomly assigned to one of three treatment groups. Group A (50 cows) was treated with 62.5 mg of intramammary amoxicillin every 12 h for three milkings. Group C (50 cows) was treated with 200 mg of intramammary cephapirin every 12 h for two milkings. Group O (71 cows) was treated with 100 U of intramuscular oxytocin every 12 h for three milkings. Clinical cure rates did not differ among treatment groups. The cost per episode of clinical mastitis was higher ($54.47) for group C than for groups A ($38.53) or O ($34.88). Group O had a higher incidence of relapse (41%), and a greater percentage of group O cows (65%) experienced an additional mastitic event in the enrolled lactation than did cows in groups A and C. Treatment had no effect on the mean number of nonsalable milkings (24.7) associated with mastitis in the lactation interval subsequent to enrollment on the trial. Twenty-two percent of the cows accrued more than 30 nonsalable milkings and produced 55% of the total nonsalable milkings associated with mastitis. There was no treatment effect on total milk production, fat production, or time to removal of the enrolled cows from the herd.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Amoxicillin,
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Bacterial Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Cephalosporins,
http://linkedlifedata.com/resource/pubmed/chemical/Cephapirin,
http://linkedlifedata.com/resource/pubmed/chemical/Oxytocin,
http://linkedlifedata.com/resource/pubmed/chemical/Penicillins
|
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
0022-0302
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
78
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
2086-95
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:8550918-Amoxicillin,
pubmed-meshheading:8550918-Animals,
pubmed-meshheading:8550918-Anti-Bacterial Agents,
pubmed-meshheading:8550918-Cattle,
pubmed-meshheading:8550918-Cephalosporins,
pubmed-meshheading:8550918-Cephapirin,
pubmed-meshheading:8550918-Cost-Benefit Analysis,
pubmed-meshheading:8550918-Dairying,
pubmed-meshheading:8550918-Female,
pubmed-meshheading:8550918-Lactation,
pubmed-meshheading:8550918-Mammary Glands, Animal,
pubmed-meshheading:8550918-Mastitis, Bovine,
pubmed-meshheading:8550918-Oxytocin,
pubmed-meshheading:8550918-Penicillins,
pubmed-meshheading:8550918-Recurrence
|
pubmed:year |
1995
|
pubmed:articleTitle |
Financial analysis of alternative treatments for clinical mastitis associated with environmental pathogens.
|
pubmed:affiliation |
University of California, Davis 95616, USA.
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|